Adzic-Vukicevic, Tatjana (56888756300)Tatjana (56888756300)Adzic-VukicevicVelickovic, Jelena (29567657500)Jelena (29567657500)VelickovicRadovanovic-Spurnic, Aleksandra (57191847101)Aleksandra (57191847101)Radovanovic-SpurnicVelickovic, Dejan (14072144000)Dejan (14072144000)VelickovicMilenkovic, Sara (57806830600)Sara (57806830600)MilenkovicPetrovic, Filip (57205176589)Filip (57205176589)PetrovicMicic, Jelena (7005054108)Jelena (7005054108)MicicDragutinovic, Natasa (57211055612)Natasa (57211055612)Dragutinovic2025-06-122025-06-122022https://doi.org/10.3855/jidc.16256https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134291543&doi=10.3855%2fjidc.16256&partnerID=40&md5=2fb1ad3ecb46bc54a3b32f059de28301https://remedy.med.bg.ac.rs/handle/123456789/3503Introduction: Multi-organ dysfunction caused by thromboembolic complications may complicate the course of SARS-CoV-2 infection. Most patients require anticoagulant therapy which predisposes them to the development of hemorrhagic syndrome. In critically ill COVID-19 patients secondary infections due to opportunistic pathogens are associated with a high mortality rate. Case report: Herein, we present a COVID-19 patient with severe hemorrhage at unusual sites complicated with invasive candidiasis and an extensively drug-resistant (XDR) strain of Klebsiella enterobacter. Conclusions: Clinicians should be aware of the possibility for invasive fungal infections in severely ill patients with SARS-CoV-2 infection due to pre-existing conditions, risk factors, and COVID-19 associated pathological mechanisms. Management of invasive candidiasis is challenging because of the high prevalence of comorbidities, risk of toxicities, and drug interactions. Copyright © 2022 Adzic-Vukicevic et al.candidaCOVID-19hemorrhageoperationresistance